PT
● MODULE 15 / 20
CNS Drugs, Epilepsy & Anesthesia
Understand sedation, psychiatric drugs, seizure control, movement disorders and anesthesia through transmitter systems.
Quick revision ↓ Medical Dictionary
FULL CHAPTER EXPLANATION
Deep Learning — Module 15
Read this section in sequence. It moves from drug targets to therapeutic effects, adverse reactions and safe use.
01
Sedation and anesthesia
Benzodiazepines enhance GABA-A receptor responses and increase the frequency of chloride-channel opening in the presence of GABA. Barbiturates prolong opening and have a narrower safety margin. Sedation can progress to respiratory depression, especially with other depressants. Propofol is an intravenous anesthetic with cardiovascular and respiratory effects; ketamine antagonizes NMDA receptors and has a distinct dissociative profile. Volatile anesthetics vary in potency and kinetics. Local anesthetics block voltage-gated sodium channels, with systemic toxicity affecting brain and heart.
02
Antiseizure drugs
Choice depends on seizure type, comorbidity and reproductive considerations. Phenytoin and carbamazepine reduce repetitive firing through sodium-channel effects; ethosuximide inhibits T-type calcium currents relevant to absence seizures. Valproate has multiple mechanisms and serious reproductive risks. Levetiracetam binds SV2A; lamotrigine also reduces excitatory transmission. Abrupt withdrawal can destabilize seizure control. Monitor drug-specific organ toxicity, interactions and serious rash rather than treating all antiseizure medicines as one uniform class.
03
Psychosis, depression and mania
Many antipsychotics block D2 receptors, with differing effects at serotonin and other targets. Extrapyramidal symptoms, prolactin elevation, metabolic effects and QT changes vary by drug. SSRIs inhibit serotonin reuptake; therapeutic mood improvement is delayed despite early transporter effects. MAO inhibitors have important food and drug interactions. Lithium can stabilize mood but has a narrow therapeutic margin and renal handling sensitive to sodium and fluid balance; thiazides, NSAIDs and some renin-angiotensin drugs can increase levels.
04
Movement disorders and stimulants
Levodopa enters the brain and is converted to dopamine; carbidopa reduces peripheral conversion without substantially crossing the blood-brain barrier. Dyskinesias, fluctuations and neuropsychiatric effects can complicate treatment. Dopamine agonists, MAO-B inhibitors and COMT inhibitors have complementary roles in selected patients. Centrally acting antimuscarinics can help some symptoms but impair cognition. Methylphenidate and amphetamine-type stimulants enhance monoaminergic transmission and require indication-specific monitoring for sleep, appetite and cardiovascular effects.
05
Toxic syndromes and integrated safety
Serotonin toxicity can follow interacting serotonergic medicines and features neuromuscular hyperactivity, autonomic disturbance and altered mental state. Neuroleptic malignant syndrome is associated with dopamine antagonism and typically marked rigidity and fever. Malignant hyperthermia is a susceptible-patient reaction to certain anesthetic triggers and is treated through emergency protocols including dantrolene. Flumazenil can reverse benzodiazepine effects but may precipitate seizures in dependent patients or mixed overdoses. Mechanistic antidote matching must never replace airway and supportive assessment.
High-Yield Revision
- Anesthetic paralysis, unconsciousness and analgesia are separate components.
- Seizure type determines drug suitability.
- Lithium exposure changes with renal function, sodium balance and interacting drugs.
Common Exam & Concept Pitfalls
- An SSRI does not produce full antidepressant benefit after one dose.
- Flumazenil is not a routine safe antidote for every mixed sedative overdose.
Sources & Further Reading
Curriculum scope checked 23 September 2026. These original study notes summarize established principles; current institutional guidance and product information govern clinical use. Faculty review is pending.
RAHBAR study structure: target → drug action → therapeutic use → adverse effects → monitoring. Use institutional curriculum and faculty guidance for local sequencing, practical requirements and assessment specifications.